Elite Pharmaceuticals, Inc. (ELTP) Return on equity 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
45.4%FY2026 · since FY2017: 14.9% → 45.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | 45.4% | +53.4 pp |
| FY2025 | -8.1% | -43.0 pp |
| FY2024 | 34.9% | +22.6 pp |
| FY2023 | 12.3% | -23.0 pp |
| FY2022 | 35.3% | +3.8 pp |
| FY2021 | 31.5% | +52.5 pp |
| FY2020 | -21.0% | — |
| FY2018 | -80.3% | -95.2 pp |
| FY2017 | 14.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice